Industry News/Clinical Trial

Company Initiates Leuvectin Gene Therapy Trial

Published in Gene Therapy Weekly, April 24th, 1995

Vical Incorporated, San Diego, California, announced that it has initiated clinical testing of its Leuvectin cancer gene therapy product at the Arizona Cancer Center in Tucson.

The Phase I/II clinical trial, which is expected to enroll 25 patients with advanced solid malignancies or lymphoma, is the company's second gene therapy product candidate to enter clinical trials. Dr. Evan Hersh is the principal investigator for the trial, which will evaluate the safety and biological activity of the experimental gene therapy.

Earlier in 1995, Vical received the necessary allowances from the U.S. National Institutes of Health (NIH) Recombinant Advisory...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-04-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry